Catalent Agrees to Biosimilar Development Collaboration with Zhejiang Hisun Pharma

Development to Employ Catalent’s Leading GPEx® Cell Line Technology for Chinese Market

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Catalent’s GPEx technology enables HISUN to bring its current bioreactor capacity to full operation, at a faster pace.

Somerset, N.J. & Taizhou City, Zhejiang Province, China (PRWEB) April 03, 2014

Catalent Pharma Solutions, the leading global provider of development solutions and advanced delivery technologies for drug, biologic and consumer health products, today announced the signing of an agreement with Zhejiang HISUN Pharmaceuticals Co. Ltd. (HISUN), to provide HISUN with a broad range of biosimilar cell lines, using Catalent’s proprietary GPEx® technology for the Chinese market. The development and manufacturing programs will benefit from the GPEx technology’s proven capability to produce very stable and high yielding cell lines.

Under the agreement, HISUN will produce a broad range of biosimilars, including infliximab, adalimumab and alemtuzumab, using Catalent’s GPEx cell lines.

Barry Littlejohns, President of Catalent’s Advanced Delivery Technologies business, commented, “We are keen to grow our biologics and development customer base throughout the Asia-Pacific region and intend to extend our global leadership in advanced delivery technologies and expert services throughout the region. We believe that the GPEx technology will enable HISUN to bring its products to market faster.”

Haibin Wang, Senior VP of HISUN, added, “As one of the leading pharma companies in China, we constantly evaluate technologies that can accelerate the progress of therapeutics for our patients. Catalent’s GPEx technology enables HISUN to bring its current bioreactor capacity to full operation, at a faster pace. We are excited about this collaboration because it heightens the quality and efficiency of our products’ development and enriches our pipeline products.”

In 2013, Catalent announced two joint ventures in China for its Softgel Technologies and Clinical Supply Solutions businesses to support customers within the Asia-Pacific region. Since then, the company has completed the acquisition of a majority share in Haining-based, privately held Zhejiang Jiang Yuan Tang Biotechnology Co. Ltd., and continues to invest in people and equipment to produce Catalent R P Scherer softgel technologies. Catalent’s new 31,000 sq ft facility in Shanghai opened on November 8th, 2013 and has become the first site in China to provide end-to-end solutions for clinical trial supplies.

Catalent’s proprietary GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency, getting drug development projects to clinic in one-third the time of traditional approaches. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, to commercial scale production. Catalent has also exclusively licensed the SMARTag™ advanced antibody-drug conjugate technology and completed construction of its new single-use Biomanufacturing Center of Excellence in Madison, WI, USA.

About Zhejiang HISUN Pharmaceuticals Co. Ltd.
Founded in 1956, Zhejiang HISUN Pharmaceuticals Co. Ltd.’s mission it “To be persistent in pharmaceutical innovation for human’s wellbeing”. The company’s vision is to become “a widely respected global pharmaceutical provider”. It focuses on the integration of pharmaceutical research and development (R&D) with production resources in order to provide its global customers with outstanding products and services. To date over 40 of the company’s products have passed certification by the FDA (US), EDQM (EU), TGA (Australia), KFDA (Korea) etc and are sold to more than 30 countries worldwide.

About Catalent

Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in Fiscal 2013 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™


Contact

  • Richard Kerns
    Northern Exposure PR
    +44 (0) 7974 579202
    Email